Top
A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients
Type d'étude
Clinical Trials Phase I-III
Maladies
Complications: infectious
Groupe
Infectious Diseases Working Party (IDWP)
Transplant Complications Working Party (TCWP)
Type de traitement
 
Investigateur principal